<![CDATA[Rezatapopt Yields Responses, Supports NDA Plan in Ovarian Cancer]]>

Data ReadoutpositiverezatapoptPositive

AI Analysis

Summary

Updated interim PYNNACLE trial data demonstrated a 46% response rate with rezatapopt monotherapy in platinum-resistant/refractory ovarian cancer, supporting the company's plan to file an NDA.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

46% response rate with rezatapopt monotherapy in platinum-resistant/refractory ovarian cancer

Importance:7/10

Sentiment:

0.75

ovarian cancerPYNNACLE trialmonotherapyplatinum-resistantNDAinterim data

Read the original article

Published by Cancer Network on September 1, 2026 4:00 PM

Read Original